Department of Nephrology, Clínico University Hospital, INCLIVA, Universitat de València, Valencia, Spain.
Department of Nephrology, Hospital Universitario Dr Peset, Universitat de València, Valencia, Spain.
Nephrol Dial Transplant. 2022 Feb 25;37(3):522-530. doi: 10.1093/ndt/gfab003.
Hyperkalaemia is a common condition in patients with comorbidities such as chronic kidney disease (CKD) or congestive heart failure (HF). Moreover, severe hyperkalaemia is a potentially life-threatening condition that is associated with a higher risk of adverse clinical events such as ventricular arrhythmias and sudden cardiac death. Currently, data regarding the prognostic implications of chronic hyperkalaemia are available; however, information about the long-term clinical consequences after an episode of severe hyperkalaemia remains scarce. The objective of this study was to evaluate the association between the trajectory of potassium measurements in patients with acute hyperkalaemia and long-term all-cause mortality.
This is a retrospective observational study that included patients with acute severe hyperkalaemia [potassium (K) >6 mEq/L] without haemolysis in the emergency room of Dr Peset University Hospital in Valencia, Spain searching the lab database from January 2016 to March 2017. The multivariable-adjusted association of serum potassium with mortality was assessed by using comprehensive state-of-the-art regression methods that can accommodate time-dependent exposure modelling.
We found 172 episodes of acute hyperkalaemia in 160 patients in the emergency room. The mean ± standard deviation age of the sample was 77 ± 12 years and 60.5% were males. The most frequent comorbidities were CKD (71.2%), HF (35%) and diabetes mellitus (56.9%). Only 11.9% of the patients were on chronic dialysis. A quarter of the patients did not have previous CKD, making hyperkalaemia an unpredictable life-threatening complication. During the acute episode, mean potassium and estimated glomerular filtration rate (eGFR) were 6.6 ± 0.6 (range 6.1-9.2) mEq/L and 23 ± 16 (range 2-84) mL/min/1.73 m2, respectively. After a median (interquartile range) follow-up of 17.3 (2.2-23.7) months, 68 patients died (42.5%). Recurrences of hyperkalaemia (K >5.5 mEq/L) were detected in 39.5% of the patients who were monitored during follow-up. We found that previous potassium levels during an acute severe hyperkalaemia episode were not predictors of mortality. Conversely, the post-discharge longitudinal trajectories of potassium were able to predict all-cause mortality (overall P = 0.0015). The effect of transitioning from hyperkalaemia to normokalaemia (K >5.5 mEq/L to K ≤5.5 mEq/L) after the acute episode was significant, and inversely associated with the risk of mortality.
Potassium levels prior to a severe hyperkalaemic event do not predict mortality. Conversely, following an episode of acute severe hyperkalaemia, serial kinetics of potassium trajectories predict the risk of death. Further evidence is needed to confirm these findings and clarify the optimal long-term management of these patients.
高钾血症是伴有慢性肾脏病(CKD)或充血性心力衰竭(HF)等合并症的患者的常见病症。此外,严重高钾血症是一种潜在的危及生命的病症,与室性心律失常和心源性猝死等不良临床事件的风险增加相关。目前,已有关于慢性高钾血症预后意义的数据;然而,关于严重高钾血症发作后长期临床后果的信息仍然很少。本研究的目的是评估急性高钾血症患者钾测量轨迹与长期全因死亡率之间的关联。
这是一项回顾性观察性研究,纳入了西班牙巴伦西亚市佩塞特大学医院急诊科急性严重高钾血症(血钾(K)>6 mEq/L)且无溶血的患者,检索了 2016 年 1 月至 2017 年 3 月的实验室数据库。使用能够适应时间依赖性暴露建模的综合最先进回归方法评估血清钾与死亡率的多变量调整关联。
我们在急诊科发现了 160 名患者的 172 次急性高钾血症发作。样本的平均年龄为 77 ± 12 岁,60.5%为男性。最常见的合并症是 CKD(71.2%)、HF(35%)和糖尿病(56.9%)。只有 11.9%的患者接受慢性透析。四分之一的患者没有先前的 CKD,使高钾血症成为一种不可预测的危及生命的并发症。在急性发作期间,平均钾和估算肾小球滤过率(eGFR)分别为 6.6 ± 0.6(范围 6.1-9.2)mEq/L 和 23 ± 16(范围 2-84)mL/min/1.73 m2。中位(四分位间距)随访 17.3(2.2-23.7)个月后,有 68 名患者死亡(42.5%)。在接受随访的患者中,检测到 39.5%的患者血钾(K>5.5 mEq/L)再次升高。我们发现,急性严重高钾血症发作期间的先前钾水平不是死亡的预测因素。相反,急性发作后出院后的钾纵向轨迹能够预测全因死亡率(总体 P=0.0015)。从高钾血症过渡到低钾血症(K>5.5 mEq/L 到 K≤5.5 mEq/L)后的效果显著,与死亡风险呈负相关。
严重高钾血症发作前的钾水平不能预测死亡率。相反,在急性严重高钾血症发作后,钾轨迹的连续动力学可预测死亡风险。需要进一步的证据来证实这些发现,并阐明这些患者的最佳长期管理。